SAMUEL MAYEDA: Open Payments
NPI 1487716544 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$551 in 23 payments from 18 companies in 2025. Trend: 2023 $1,276 · 2024 $965 · 2025 $551
Food & beverage: $551
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 3 | $81 |
| Insulet Corporation | 1 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $40 |
| Amgen Inc. | 2 | $34 |
| IBSA Pharma Inc. | 2 | $34 |
| Sandoz Inc. | 1 | $32 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $32 |
| Exact Sciences Corporation | 1 | $31 |
| ABBVIE INC. | 1 | $30 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $27 |
Products named: LEQVIO, Omnipod, JARDIANCE, REPATHA, Tirosint, Kerendia, Cologuard Collection Kit, QULIPTA.
Industry payments across CA — which companies pay providers there.
